Study: TheraTears Nutrition improves eye health
WOBURN, Mass. — Advanced Vision Research on Monday announced results from a pilot trial published in the journal Cornea that demonstrated a reduction in dry-eye symptoms and an increase in tear volume and tear flow for those patients taking TheraTears Nutrition, an optimized blend of omega-3 oils.
Almost 3-in-4 symptomatic dry-eye patients who received the omega-3 supplement reported having no symptoms of dry eye after 90 days. In the placebo group, only 7% had a complete reduction of symptoms.
The study also found that supplementation with TheraTears Nutrition, when compared with the placebo, resulted in 0.10 microliters/min. higher tear flow and 0.94 microliters higher tear volume, two objective parameters that are key to the improvement of disease in patients with dry eye.
Perrigo to buy Paddock for $540 million
ALLEGAN, Mich. — Perrigo will buy Paddock Labs for more than half a billion dollars, Perrigo said Thursday.
Perrigo, an Allegan, Mich.-based company that makes generic prescription and over-the-counter drugs, including private-label products, announced that it would buy Minneapolis-based Paddock for $540 million in cash.
“This acquisition is an important step forward in executing on our strategy to expand our specialty portfolio of generic prescription drug products,” Perrigo chairman and CEO Joseph Papa said. “It adds incremental scale, as well as excellent development and manufacturing capabilities across a spectrum of niche dosage forms.”
Second half of cold season holds promise
SCOTTSDALE, Ariz. — Cough-cold supplier Matrixx on Thursday credited tough comparisons against the prior season’s high pre-season inventory purchases by retailers due to the publicity of the H1N1 flu outbreak for the lower level of sales for the quarter ended Dec. 31, 2010.
The company reported net sales of $20.3 million, down 29%. However, a lift in late December cough-cold illness rates holds promise for the second half of the season.
“We began to see increases in consumer purchases of our products during [late November, December] as new advertising commenced and the incidence of illness surpassed last year’s illness level,” said Bill Hemelt, Matrixx president and CEO. “Retailers continued to trim their inventory levels in comparison to last year; however, we believe retailers’ inventory of our products has reached a point where they will increase purchases to offset the increased consumer takeaway,” he said.
“For the four weeks ended Dec. 26, 2010, retail unit sales (three-outlet syndicated scanner data, not including Walmart or club stores) of Zicam Cold Remedy oral delivery products increased approximately 30%, while the total cough-cold category increased approximately 5% compared to the prior year," Hemelt added. "For the full fiscal year ending March 31, 2011, we anticipate revenue increasing 3% to 5% above the $67.3 million achieved in fiscal 2010."